Literature DB >> 25060016

ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance.

Alessio Mattesini1, Gioel G Secco2, Gianni Dall'Ara3, Matteo Ghione3, Juan C Rama-Merchan3, Alessandro Lupi4, Nicola Viceconte3, Alistair C Lindsay3, Ranil De Silva3, Nicolas Foin5, Toru Naganuma6, Serafina Valente7, Antonio Colombo6, Carlo Di Mario8.   

Abstract

OBJECTIVES: The aim of this study was to compare the acute performance of the PLLA ABSORB bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, California) with second-generation metal drug-eluting stents (DES) in complex coronary artery lesions.
BACKGROUND: Thick polymer-based BVS have different mechanical properties than thin second-generation DES. Data on the acute performance of BVS are limited to simple coronary lesions treated in trials with strict inclusion criteria.
METHODS: Fifty complex coronary lesions (all type American College of Cardiology/American Heart Association B2-C) treated with a BVS undergoing a final optical coherence tomography (OCT) examination were compared with an equal number of matched lesions treated with second-generation DES. The following stent performance indexes were assessed with OCT: mean and minimal area, residual area stenosis (RAS), incomplete strut apposition (ISA), tissue prolapse, eccentricity index, symmetry index, strut fracture, and edge dissection.
RESULTS: One hundred lesions from 73 patients were analyzed. A higher balloon diameter/reference vessel diameter ratio was used for predilation in the BVS group (p < 0.01). Most of the BVS and DES were post-dilated with short noncompliant (NC) balloons of similar diameter. OCT showed in the BVS group a higher tissue prolapse area (p = 0.08) and greater incidence of ISA at the proximal edge (p = 0.04) with no difference in the overall ISA. The RAS was 20.2% in the BVS group and 21.7% in the DES group (p = 0.32). There was no difference in the eccentricity index. The minimal and mean lumen areas were similar in the 2 groups. Two cases of strut fractures occurred after the BVS, whereas none was observed in the DES.
CONCLUSIONS: Based on OCT, the BVS showed similar post-procedure area stenosis, minimal lumen area, and eccentricity index as second-generation DES. The different approach for lesion preparation and routine use of OCT guidance during BVS expansion may have contributed to these results.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bioresorbable vascular scaffold; drug-eluting stent; optical coherence tomography; stent

Mesh:

Substances:

Year:  2014        PMID: 25060016     DOI: 10.1016/j.jcin.2014.01.165

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  32 in total

1.  Clinical performance of a novel ultrathin strut, low-dose, sirolimus-eluting stent with abluminal-only biodegradable polymeric coating for patients undergoing percutaneous coronary intervention in the daily practice.

Authors:  Guy F A Prado; Expedito E Ribeiro; Pedro H M C Melo; Fabio A Pinton; Antonio Esteves-Filho; Celso K Takimura; Jose Mariani; Luiz J Kajita; Gilberto Marchiori; Breno de Alencar Araripe Falcao; Micheli Z Galon; Paulo R Soares; Silvio Zalc; Pedro A Lemos
Journal:  Cardiovasc Diagn Ther       Date:  2015-12

2.  Bioresorbable vascular scaffold overlap evaluation with optical coherence tomography after implantation with or without enhanced stent visualization system (WOLFIE study): a two-centre prospective comparison.

Authors:  Simone Biscaglia; Gianluca Campo; Matteo Tebaldi; Carlo Tumscitz; Rita Pavasini; Luca Fileti; Gioel G Secco; Carlo Di Mario; Roberto Ferrari
Journal:  Int J Cardiovasc Imaging       Date:  2015-09-01       Impact factor: 2.357

3.  Bioresorbable vascular scaffolds for complex coronary anatomies: "Icarus' flight" for interventional cardiologists?

Authors:  Salvatore Cassese; Adnan Kastrati; Massimiliano Fusaro
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

4.  Overlapping implantation of bioresorbable novolimus-eluting scaffolds: an observational optical coherence tomography study.

Authors:  Florian Blachutzik; Niklas Boeder; Jens Wiebe; Alessio Mattesini; Oliver Dörr; Astrid Most; Timm Bauer; Monique Tröbs; Jens Röther; Christian Schlundt; Stephan Achenbach; Christian Hamm; Holger Nef
Journal:  Heart Vessels       Date:  2016-12-21       Impact factor: 2.037

5.  Bioresorbable scaffolds: should we stay simple or go complex?

Authors:  Luis Ortega-Paz; Salvatore Brugaletta; Hector M Garcia-Garcia; Manel Sabaté
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

Review 6.  Bioresorbable vascular scaffolds - basic concepts and clinical outcome.

Authors:  Ciro Indolfi; Salvatore De Rosa; Antonio Colombo
Journal:  Nat Rev Cardiol       Date:  2016-09-29       Impact factor: 32.419

Review 7.  Invasive assessment of coronary artery disease.

Authors:  Stylianos A Pyxaras; William Wijns; Johan H C Reiber; Jeroen J Bax
Journal:  J Nucl Cardiol       Date:  2017-08-28       Impact factor: 5.952

Review 8.  Bioresorbable Coronary Scaffolds: Deployment Tips and Tricks and the Future of the Technology.

Authors:  J Ribamar Costa; Alexandre Abizaid
Journal:  Methodist Debakey Cardiovasc J       Date:  2018 Jan-Mar

9.  Procedural findings and early healing response after implantation of a self-apposing bioresorbable scaffold in coronary bifurcation lesions.

Authors:  Emil Nielsen Holck; Camilla Fox-Maule; Trine Ørhøj Barkholt; Lars Jakobsen; Shengxian Tu; Michael Maeng; Jouke Dijkstra; Evald Høj Christiansen; Niels Ramsing Holm
Journal:  Int J Cardiovasc Imaging       Date:  2019-05-04       Impact factor: 2.357

10.  Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects.

Authors:  Florian Blachutzik; Niklas Boeder; Jens Wiebe; Alessio Mattesini; Oliver Dörr; Astrid Most; Timm Bauer; Jens Röther; Monique Tröbs; Christian Schlundt; Stephan Achenbach; Christian W Hamm; Holger M Nef
Journal:  Clin Res Cardiol       Date:  2016-10-18       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.